Changeflow GovPing Pharma & Drug Safety Panobinostat Combination Therapy for Cholangioc...
Routine Notice Added Final

Panobinostat Combination Therapy for Cholangiocarcinoma Treatment

Favicon for changeflow.com ChangeBridge: Patent Apps - Therapeutics (A61P)
Published April 2nd, 2026
Detected April 2nd, 2026
Email

Summary

The USPTO published patent application US20260091021A1 covering combination therapies comprising panobinostat for treating cholangiocarcinoma. The application (No. 19413668, filed December 9, 2025) names seven inventors and claims pharmaceutical compositions combining panobinostat with cytotoxic agents.

What changed

The USPTO published a patent application for combination therapies using panobinostat with cytotoxic agents to treat cholangiocarcinoma. The application claims pharmaceutical compositions and methods of treatment, with CPC classifications covering various therapeutic compound combinations including A61K 31/4045 (panobinostat) and multiple cytotoxic agent categories.

This is a published patent application creating no immediate compliance obligations. Inventors and patent practitioners should note the filing date of December 9, 2025 and publication date. Pharmaceutical researchers and drug developers may want to review freedom-to-operate implications for cholangiocarcinoma combination therapies.

Source document (simplified)

← USPTO Patent Applications

COMBINATION THERAPIES COMPRISING PANOBINOSTAT FOR THE TREATMENT OF CHOLANGIOCARCINOMA

Application US20260091021A1 Kind: A1 Apr 02, 2026

Inventors

Theresa AHRENS, Alexandra GADE, Eivind HOVIG, Jo KLAVENESS, Johannes LANDSKRON, Kjetil TASKEN, Tove Cecilie VIEBE

Abstract

The present invention relates to compositions and methods for treatment of cholangiocarcinoma and in particular to combination therapies comprising panobinostat compositions in combination with other cytotoxic agents, e.g. agents that potentiate the effects of panobinostat, for use in the treatment of cholangiocarcinoma. Pharmaceutical compositions comprising panobinostat and other cytotoxic agents are also provided.

CPC Classifications

A61K 31/4045 A61K 31/09 A61K 31/185 A61K 31/282 A61K 31/337 A61K 31/352 A61K 31/365 A61K 31/404 A61K 31/4545 A61K 31/4706 A61K 31/4745 A61K 31/506 A61K 31/517 A61K 31/519 A61K 31/5377 A61K 31/5517 A61K 31/704 A61K 33/243 A61P 35/00

Filing Date

2025-12-09

Application No.

19413668

View original document →

Named provisions

Combination Therapies Comprising Panobinostat Methods for Treatment of Cholangiocarcinoma

Classification

Agency
USPTO
Published
April 2nd, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260091021A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent Filing Pharmaceutical Research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: Patent Apps - Therapeutics (A61P) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.